Deroy & Devereaux Private Investment Counsel Inc. Has $202,000 Holdings in Pfizer Inc. (NYSE:PFE)

Deroy & Devereaux Private Investment Counsel Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 20.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,625 shares of the biopharmaceutical company’s stock after selling 1,982 shares during the quarter. Deroy & Devereaux Private Investment Counsel Inc.’s holdings in Pfizer were worth $202,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Swiss National Bank boosted its holdings in shares of Pfizer by 0.6% in the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company’s stock valued at $486,762,000 after buying an additional 100,900 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock valued at $3,766,366,000 after acquiring an additional 12,864,343 shares during the last quarter. Empowered Funds LLC grew its position in shares of Pfizer by 80.9% in the 3rd quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company’s stock valued at $14,709,000 after acquiring an additional 227,349 shares during the period. Addison Advisors LLC increased its stake in shares of Pfizer by 394.2% during the 3rd quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company’s stock worth $1,512,000 after purchasing an additional 41,668 shares during the last quarter. Finally, KBC Group NV raised its holdings in shares of Pfizer by 26.0% in the 3rd quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company’s stock valued at $89,872,000 after purchasing an additional 639,985 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on PFE. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Finally, Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Trading Down 1.5 %

Shares of PFE stock opened at $26.51 on Monday. The stock has a 50 day simple moving average of $26.27 and a 200 day simple moving average of $27.86. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $150.20 billion, a P/E ratio of 35.82, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.49%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.